In vivo relevance of the Schlafen-mediated innate immune mechanism in flavivirus infection
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 1R16AI167830-01A1
Grant search
Key facts
Disease
UnspecifiedStart & end year
20232027Known Financial Commitments (USD)
$151,360Funder
National Institutes of Health (NIH)Principal Investigator
ASSOCIATE PROFESSOR Manuel LlanoResearch Location
United States of AmericaLead Research Institution
University Of Texas El PasoResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
ABSTRACT Flaviviruses are important human pathogens including viruses such as West Nile, dengue, and Zika. No specific treatments or vaccines are available against these infections, and no biomarkers exist that allow predicting their outcome, characterized by important clinical variability. Understanding innate antiviral immune responses against flaviviruses, could lead to the identification of disease susceptibility biomarkers and therapeutic targets. We recently demonstrated that the type I interferon-stimulated protein Schlafen 11 (SLFN11) is a novel and potent flavivirus restriction factor. In this application we aim to define, at the molecular level, several aspects of the mechanism of action of SLFN11 and determine the anti-flavivirus activity of other members of the SLFN family, as well as the in vivo relevance of this defense system. Therefore, this investigation is highly relevant and will significantly advance our understanding of the antiviral mechanism of action of SLFN proteins, which is currently unknown.